Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204704 | 0.89 | KDM4E (0.40) | MEN1KMT2ALMNASMN1; SMN2RAB9A | |
| SCHEMBL4196022 | 0.86 | KDM4E (0.38) | MEN1KMT2ALMNARAB9AMAPT | |
| SCHEMBL4193372 | 0.85 | PPARA (0.46) | SMN1; SMN2NPC1RAB9AMAPTMAPK1 | |
| SCHEMBL4190462 | 0.84 | KDM4E (0.44) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL4198605 | 0.82 | KDM4E (0.36) | MEN1KMT2ARAB9AALDH1A1KDM4E | |
| SCHEMBL4198178 | 0.82 | FFAR4 (0.42) | MEN1KMT2ALMNASMN1; SMN2MAPT | |
| SCHEMBL4198432 | 0.82 | PPARA (0.43) | ALDH1A1KDM4E | |
| SCHEMBL4194269 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AL3MBTL1HPGDMAPK1 | |
| SCHEMBL4197471 | 0.76 | PPARG (0.41) | MAPTL3MBTL1 | |
| SCHEMBL4198157 | 0.76 | FFAR4 (0.41) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627867-B1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-7534909-B2 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1627867-A1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | METTL14, PAM, TAS2R41 | MEN1 744/4885KMT2A 266/4885LMNA 4549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.